The AGM statement from Fusion Antibodies (FAB.L) provides some unaudited figures for H1 FY26 ahead of its interim results, typically due in December. These show FY26 H1 revenue of c. £838k with a higher gross margin of 30% and period end cash of £251k. Although half on half revenue fell, we consider this to be creditable performance given the extremely challenging background given the very depressed state of the biotech markets and the economic uncertainty and disruption then present in the US e ....
